Sermorelin Side Effects

Known side effects

The following side effects have been reported in clinical trials for Sermorelin:

• Injection site reactions including redness, swelling, and itching reported in approximately 16% of patients in clinical trials (PMID: 18031173)
• Transient facial flushing, most commonly reported during the first few weeks of treatment (PMID: 18031173)
• Headache, typically mild and resolving within the first month of use
• Vivid dreams reported frequently — generally considered a sign of enhanced slow-wave sleep rather than an adverse effect
• Potential decrease in insulin sensitivity with long-term GH secretagogue use — blood glucose monitoring recommended for at-risk individuals (PMID: 28400207)
• Mild nausea or dizziness during the first few weeks, typically resolving with continued use
• Water retention and mild bloating, particularly in hands and feet, more common at higher doses or when combined with GHRPs
• Joint pain or stiffness reported occasionally, consistent with effects seen from GH elevation from any source
• One clinical trial of a growth hormone secretagogue (not sermorelin specifically) was halted early due to concerns about congestive heart failure risk — causality was not established (PMID: 28400207)
• Theoretical cancer risk: elevated IGF-1 levels have been epidemiologically associated with certain cancers — no sermorelin-specific cancer data exists, and clinical trials have not shown increased cancer incidence, but long-term studies are lacking (PMID: 28400207)
• Carpal tunnel-like symptoms reported in community settings, more commonly when sermorelin is combined with GHRPs at higher doses
• Diminished response over time in some users — pituitary sensitivity to GHRH stimulation may decrease with aging, and treatment effects on sleep-endocrine activity are attenuated in elderly vs young subjects (PMID: 9390775)
• Sermorelin is prohibited by WADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) at all times, in and out of competition

Severity and frequency

Clinical trial data provides specific frequency data for Sermorelin side effects. Most common side effects are mild to moderate and often improve with continued use or dose adjustment.

When to seek medical attention

Contact your healthcare provider immediately if you experience:

• Severe or persistent symptoms that do not improve
• Signs of an allergic reaction (rash, swelling, difficulty breathing)
• Severe abdominal pain
• Changes in vision or neurological symptoms
• Any symptom that concerns you

Risk factors

Side effect risk may be higher in certain populations. Discuss your complete medical history with your doctor, including:

• Pre-existing medical conditions
• Current medications (drug interactions)
• Pregnancy or plans to become pregnant
• History of allergic reactions to peptides or similar compounds
• Note: Sermorelin is a research compound without established human safety data from FDA-approved clinical trials

Research references

• Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy — Journal of Clinical Endocrinology & Metabolism (1996) [PubMed]
• Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency — BioDrugs (1999) [PubMed]
• Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men — Journal of Clinical Endocrinology & Metabolism (1992) [PubMed]
• Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women — Journal of Clinical Endocrinology & Metabolism (1997) [PubMed]
• Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men — Metabolism (1997) [PubMed]
• Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial — Archives of Neurology (2012) [PubMed]
• Treating age-related changes in somatotrophic hormones, sleep, and cognition — Dialogues in Clinical Neuroscience (2001) [PubMed]
• Changes in sleep-endocrine activity after growth hormone-releasing hormone depend on time of administration — Journal of Neuroendocrinology (1997) [PubMed]
• Reduced efficacy of growth hormone-releasing hormone in modulating sleep endocrine activity in the elderly — Neurobiology of Aging (1997) [PubMed]
• Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? — Clinical Interventions in Aging (2006) [PubMed]
• Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males — Translational Andrology and Urology (2020) [PubMed]
• The Safety and Efficacy of Growth Hormone Secretagogues — Sexual Medicine Reviews (2018) [PubMed]
• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — Journal of Clinical Endocrinology & Metabolism (2006) [PubMed]
• Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels — American Journal of Men's Health (2017) [PubMed]